• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

粪便钙卫蛋白和粪便吲哚可预测艰难梭菌反复感染患者粪便微生物群移植的结果。

Fecal calprotectin and fecal indole predict outcome of fecal microbiota transplantation in subjects with recurrent Clostridium difficile infection.

作者信息

Hibbard J, Jiang Z-D, DuPont H L

机构信息

Ohio Wesleyan University, USA.

Kelsey Research Foundation, USA; University of Texas School of Public Health, USA.

出版信息

Anaerobe. 2019 Apr;56:102-105. doi: 10.1016/j.anaerobe.2019.03.006. Epub 2019 Mar 6.

DOI:10.1016/j.anaerobe.2019.03.006
PMID:30851429
Abstract

Fecal calprotectin and indole were studied in 134 subjects with recurrent CDI before and after FMT. Reduced fecal calprotectin (p = 0.0353, 95% CI 0.1305-0.1439) and rising levels of indole (p < 0.0001, 95% CI < 0.0001-0.0003) predicted successful treatment. A ratio of recal calprotectin/indole may provide prognostic value for FMT (p = 0.0004, 95% CI 0.22-0.87).

摘要

对134例复发性艰难梭菌感染（CDI）患者在粪菌移植（FMT）前后的粪便钙卫蛋白和吲哚进行了研究。粪便钙卫蛋白降低（p = 0.0353，95%置信区间0.1305 - 0.1439）和吲哚水平升高（p < 0.0001，95%置信区间< 0.0001 - 0.0003）预示着治疗成功。粪便钙卫蛋白/吲哚比值可能为粪菌移植提供预后价值（p = 0.0004，95%置信区间0.22 - 0.87）。

相似文献

1
Fecal calprotectin and fecal indole predict outcome of fecal microbiota transplantation in subjects with recurrent Clostridium difficile infection.粪便钙卫蛋白和粪便吲哚可预测艰难梭菌反复感染患者粪便微生物群移植的结果。
Anaerobe. 2019 Apr;56:102-105. doi: 10.1016/j.anaerobe.2019.03.006. Epub 2019 Mar 6.
2
Fecal calprotectin and need of multiple microbiota trasplantation infusions in Clostridium difficile infection.粪便钙卫蛋白与艰难梭菌感染多次微生物移植输注的需求。
J Gastroenterol Hepatol. 2020 Nov;35(11):1909-1915. doi: 10.1111/jgh.15072. Epub 2020 Apr 30.
3
Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: A meta-analysis?在复发性或难治性艰难梭菌感染患者中，冷冻粪便微生物群移植与新鲜粪便微生物群移植的效果是否相同：一项荟萃分析？
Diagn Microbiol Infect Dis. 2017 Aug;88(4):322-329. doi: 10.1016/j.diagmicrobio.2017.05.007. Epub 2017 May 18.
4
Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection.炎症性肠病影响复发性艰难梭菌感染粪便微生物群移植的结果。
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1433-8. doi: 10.1016/j.cgh.2016.02.018. Epub 2016 Feb 22.
5
Successful therapy of Clostridium difficile infection with fecal microbiota transplantation.粪便微生物群移植成功治疗艰难梭菌感染
J Physiol Pharmacol. 2016 Dec;67(6):859-866.
6
Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection.用于复发性艰难梭菌感染的口服、冷冻粪便微生物群移植（FMT）胶囊。
BMC Med. 2016 Sep 9;14(1):134. doi: 10.1186/s12916-016-0680-9.
7
Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.复发性艰难梭菌感染和/或溃疡性结肠炎患者单次供体粪便微生物群移植的纵向微生物组分析
PLoS One. 2018 Jan 31;13(1):e0190997. doi: 10.1371/journal.pone.0190997. eCollection 2018.
8
Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection.艰难梭菌感染患者粪便钙卫蛋白水平、疾病严重程度与高毒力核糖体分型027菌株之间的相关性
BMC Infect Dis. 2016 Jun 22;16:309. doi: 10.1186/s12879-016-1618-8.
9
Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation.预测包裹粪菌移植后艰难梭菌感染的复发。
Microbiome. 2018 Sep 18;6(1):166. doi: 10.1186/s40168-018-0549-6.
10
Factors Associated with the Use of Fecal Microbiota Transplant in Patients with Recurrent Clostridium difficile Infections.与复发性艰难梭菌感染患者使用粪便微生物群移植相关的因素。
Infect Control Hosp Epidemiol. 2018 Mar;39(3):302-306. doi: 10.1017/ice.2017.314. Epub 2018 Jan 24.

引用本文的文献

1
Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.肠道菌群失调相关疾病的粪便微生物群移植研究进展
Adv Sci (Weinh). 2025 Apr;12(13):e2413197. doi: 10.1002/advs.202413197. Epub 2025 Feb 27.
2
infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.感染：历史、流行病学、风险因素、预防、临床表现、治疗和未来选择。
Clin Microbiol Rev. 2024 Jun 13;37(2):e0013523. doi: 10.1128/cmr.00135-23. Epub 2024 Feb 29.
3
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches.
利用先进的制药方法将微生物代谢物作为治疗药物进行传递。
Pharmacol Ther. 2024 Apr;256:108605. doi: 10.1016/j.pharmthera.2024.108605. Epub 2024 Feb 16.
4
The Evolving Landscape of Fecal Microbial Transplantation.粪便微生物移植的演变格局。
Clin Rev Allergy Immunol. 2023 Oct;65(2):101-120. doi: 10.1007/s12016-023-08958-0. Epub 2023 Feb 9.
5
The value of fecal calprotectin in infection: A systematic review.粪便钙卫蛋白在感染中的价值：一项系统综述。
Front Physiol. 2022 Aug 3;13:881816. doi: 10.3389/fphys.2022.881816. eCollection 2022.
6
Microbial Metabolite Regulation of Epithelial Cell-Cell Interactions and Barrier Function.微生物代谢物对上皮细胞-细胞相互作用和屏障功能的调节。
Cells. 2022 Mar 10;11(6):944. doi: 10.3390/cells11060944.
7
Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).艰难梭菌感染的诊断和治疗建议：西班牙化疗学会（SEQ）、西班牙内科学会（SEMI）和西班牙麻醉与复苏学会术后感染工作组（SEDAR）的官方临床实践指南。
Rev Esp Quimioter. 2020 Apr;33(2):151-175. doi: 10.37201/req/2065.2020. Epub 2020 Feb 20.
8
Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation.肠道微生物组在医学疾病中的异常表现和粪便微生物移植的潜在逆转作用。
Dig Dis Sci. 2020 Mar;65(3):741-756. doi: 10.1007/s10620-020-06102-y.